reports
Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earni...
Prestige Consumer Healthcare Announces Fiscal 2025 Third Quarter Earnings Results Date and ICR Conference Presentation TARRYTOWN, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 third quarter earnings release on Thursday, February 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To parti...
Prestige Consumer Healthcare Inc. Expands CFO Christine Sacco’s Role t...
Prestige Consumer Healthcare Inc. Expands CFO Christine Sacco’s Role to Include Chief Operating Officer Responsibilities TARRYTOWN, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced that Chief Financial Officer Christine Sacco’s responsibilities have been expanded to include the role of Chief Operating Officer, effective immediately. In this enhanced position as COO/CFO, Ms. Sacco will oversee the Company’s supply chain, in addition to her existing responsibilities. Ms. Sacco will continue to report to Ron L...
Prestige Consumer Healthcare Inc: 4 directors
Three Directors at Prestige Consumer Healthcare Inc sold/sold after exercising options 42,736 shares at between 81.850USD and 82.010USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionar...
Prestige Consumer Healthcare Inc. Reports Second Quarter and First Hal...
Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2025 Results Revenue of $283.8 Million in Q2, Ahead of OutlookDiluted EPS of $1.09 in Q2, Up 2% Versus Prior YearNet Cash Provided by Operating Activities of Approximately $125 Million in First Six Months, Up Approximately 13%; Reduced Debt by $75 Million and Repurchased $38 Million Shares Year-to-DateReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for it...
Prestige Consumer Healthcare to Release Fiscal 2025 Second Quarter Ear...
Prestige Consumer Healthcare to Release Fiscal 2025 Second Quarter Earnings Results TARRYTOWN, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 second quarter earnings release on Thursday, November 7, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the conference call via ph...
Prestige Consumer Healthcare to Present at the Barclays Global Consume...
Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference TARRYTOWN, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 5, 2024 at 2:15 p.m. ET. All interested parties may access a live webcast of this event at under the "Investors” section and the "Events and Presentations" tab, or by using the following link: For those unable to participate during the live webcast, a replay option will be available on the Compa...
Prestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2025 Re...
Prestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2025 Results Revenue of $267.1 Million in Q1, Ahead of Expectations, down 4.4% versus Prior YearEPS of $0.98 and Adjusted EPS of $0.90 in Q1 Compared to $1.06 in the Prior YearCash from Operations of $54.8 Million up 13.9% versus Prior Year; Reduced Debt by $35 Million and Repurchased $26 Million SharesReaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter e...
Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earn...
Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results TARRYTOWN, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 first quarter earnings release on Thursday, August 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the conference call via phon...
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual...
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference TARRYTOWN, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on Monday, June 10, 2024 at 1:30 p.m. ET. All interested parties may access a live webcast of this event at under the "Investors” section and the "Events and Presentations" tab, or by using the following link: For those unable to participate during the live webcast, a replay option...
Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results
Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain ConstraintsAchieved Leverage Ratio of 2.8x at Year-End, Below Long-Term TargetBoard of Directors Authorize New $300 Million Share Repurchase ProgramInitial Full-Year Fiscal 2025 Organic Revenue Growth and EPS Outlook of Approximately 1% and $4.40 to $4.46, respectively TARRYTOWN, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial result...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarte...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 fourth quarter and year-end earnings release on Tuesday, May 14, 2024 after the market close. The Company will host a conference call to discuss the results the following morning, May 15th, at 8:30 a.m. ET. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of...
Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected P...
Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag The nausea-fighting brand is highlighting the cultural impact of barf bags and ushering them into a new era with a documentary, a limited-edition collection of upcycled bags and a custom wearable art piece made from vintage bags TARRYTOWN, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- 1949 was a big year for barf, welcoming the invention of the barf bag and . Seventy-five years later, Dramamine, a Prestige Consumer Healthcare brand, thrives as the number one brand for motion sickness relief, but as Dr...
Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Re...
Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results Revenue of $282.7 Million in Q3, Up 2.6% Versus Prior YearDiluted EPS of $1.06 in Q3, Up 2.2% Versus Prior YearReduced Leverage Ratio to 2.9x at Quarter EndRaising Full-Year Fiscal 2024 Earnings Outlook to Approximately $4.33 TARRYTOWN, N.Y., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2023. “We are pleased with our continued strong results that exceeded our revenue and earnings expe...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1%...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene is not an ingredi...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results TARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 third quarter earnings release on Thursday, February 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the conference call v...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americai...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene TARRYTOWN, N.Y., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine Topical Anesthetic Spray to the consumer level. While benzene is not an ingredient in any Americaine® 20% Benzocaine Topical Anesthetic Spray products, a recent review by our manufacturer and their third-party lab found that a sample from one lot of the ...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2%...
Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene TARRYTOWN, N.Y., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling two lots of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder to the consumer level. A recent review by our manufacturer and their third-party lab found that samples from two lots of the product contained elevated levels of benzene. While benzene i...
Prestige Consumer Healthcare Inc. Reports Second Quarter Fiscal 2024 R...
Prestige Consumer Healthcare Inc. Reports Second Quarter Fiscal 2024 Results Revenue of $286.3 Million in Q2, Ahead of OutlookDiluted EPS of $1.07 in Q2, Up Over 5% Versus Prior YearReduced Leverage Ratio to 3.0x at Quarter EndReaffirming Full-Year Fiscal 2024 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2023. “Our second quarter results build on a strong first quarter performance thanks to our di...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Second Quarte...
Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Second Quarter Earnings Results TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2024 second quarter earnings release on Thursday, November 2, 2023 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of . To participate in the conference call v...
Prestige Consumer Healthcare to Present at the Barclays Global Consume...
Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference TARRYTOWN, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 7, 2023 at 3:00 p.m. ET. All interested parties may access a live webcast of this event at under the "Investors” section and the "Events and Presentations" tab, or by using the following link: For those unable to participate during the live webcast, a replay option will be available on t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.